Company Overview

Aspira Women’s Health Inc. is a U.S.-based healthcare and molecular diagnostics company focused on gynecologic disease detection and women’s health. The company develops and commercializes blood-based biomarker testing and risk assessment technologies intended to assist physicians in evaluating ovarian cancer risk and managing gynecologic conditions. Aspira operates primarily within the women’s health diagnostics, biotechnology, and precision medicine sectors, with a strategic emphasis on improving early detection and clinical decision-making for ovarian cancer and related diseases.

The company’s primary revenue drivers have historically included diagnostic testing services and related laboratory operations, particularly through its ovarian cancer risk assessment products. Key offerings have included OVA1 and OVERA, which are intended to aid in the assessment of adnexal masses prior to surgical intervention, as well as newer platform initiatives involving artificial intelligence and biomarker-based diagnostics. Aspira traces its origins to Vermillion, Inc., which was founded in the 1990s and later rebranded as Aspira Women’s Health Inc. as the company narrowed its focus toward women’s healthcare diagnostics and technology-enabled disease assessment.

Business Operations

Aspira Women’s Health generates revenue primarily through diagnostic test processing, laboratory services, and commercialization agreements associated with its proprietary testing platforms. The company has operated certified laboratory infrastructure in the United States to support physician-ordered testing and clinical diagnostics. Its business operations have centered around the commercialization of its ovarian cancer assessment technologies, including the OVA1 and OVERA tests, alongside software-driven risk stratification tools designed to support clinical workflows.

Operationally, the company’s activities have been concentrated largely within the U.S. healthcare market, though its technologies have had exposure to broader clinical and research collaborations. Aspira has controlled intellectual property related to biomarker algorithms, proteomic diagnostics, and AI-enhanced risk assessment platforms. Public filings and investor disclosures have also referenced partnerships and collaborations with healthcare providers, laboratory networks, and research institutions intended to expand adoption of its testing technologies. Data regarding significant international joint ventures or large-scale overseas operations remains limited based on available public sources.

Strategic Position & Investments

Aspira Women’s Health has positioned itself as a specialized participant in precision diagnostics for gynecologic disease, with strategic priorities focused on expanding its molecular testing portfolio and integrating artificial intelligence into women’s health diagnostics. The company has invested in biomarker discovery, machine-learning-enabled clinical assessment tools, and next-generation diagnostics intended to improve earlier detection and risk stratification for ovarian cancer and endometriosis. Strategic communications and public filings have emphasized the company’s objective of creating a broader women’s health diagnostic ecosystem beyond a single-product model.

The company has also pursued portfolio expansion through internal development initiatives and selective technology-related transactions. Aspira’s strategy has included leveraging data assets and proprietary algorithms to strengthen physician adoption and payer engagement. Public disclosures have referenced continued development of products associated with endometriosis detection and pelvic mass assessment. While Aspira has maintained a focused portfolio rather than a diversified multinational structure, its intellectual property and diagnostic platform strategy have remained central to its long-term positioning within women’s health diagnostics.

Geographic Footprint

Aspira Women’s Health is headquartered in Austin, Texas, and its operational footprint has primarily been concentrated in the United States healthcare market. The company’s commercial activities have largely targeted U.S.-based physicians, healthcare systems, laboratories, and patients seeking specialized ovarian cancer risk assessment and gynecologic diagnostic services. Regulatory and reimbursement dynamics within the U.S. have therefore played a significant role in shaping the company’s business strategy and market performance.

Although the company has had limited publicly disclosed international operational infrastructure compared with larger global diagnostics firms, its technologies and intellectual property have had relevance to broader global women’s health trends. Available public information indicates that Aspira’s commercial emphasis remains predominantly domestic, with international influence occurring mainly through scientific visibility, research participation, and potential licensing or collaborative opportunities rather than extensive overseas facilities or subsidiaries.

Leadership & Governance

Aspira Women’s Health evolved from the former Vermillion, Inc. corporate structure and has undergone leadership and strategic changes as it transitioned toward a more concentrated women’s health diagnostics identity. The company’s governance approach, as reflected in public filings and investor communications, has emphasized innovation in women’s healthcare, operational restructuring, clinical validation, and commercialization discipline within the diagnostics market.

Key executives and leadership figures identified in recent public disclosures include:

• Nicole Sandford – President and Chief Executive Officer
• Michael Buhle – Chief Financial Officer
• John Farlinger – Chairman of the Board
• Mark Kubik – Chief Scientific Officer

Leadership communications have generally emphasized advancing proprietary diagnostic technologies, strengthening reimbursement pathways, improving physician adoption, and expanding the company’s role in precision medicine for women’s health. Certain executive roles and board compositions may change over time based on company filings and governance updates.